...
首页> 外文期刊>AJR: American Journal of Roentgenology : Including Diagnostic Radiology, Radiation Oncology, Nuclear Medicine, Ultrasonography and Related Basic Sciences >Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.
【24h】

Hepatocellular carcinoma in liver transplantation candidates: detection with gadobenate dimeglumine-enhanced MRI.

机译:肝移植候选者的肝细胞癌:用g酸二聚丁二胺增强的MRI检测。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The purpose of this study was to retrospectively evaluate the diagnostic performance of dynamic gadobenate dimeglumine-enhanced MRI with explant pathologic correlation in the detection of hepatocellular carcinoma (HCC) in patients undergoing liver transplantation. MATERIALS AND METHODS: Forty-seven patients (28 men, 19 women; mean age, 49 years) underwent dynamic gadobenate dimeglumine-enhanced MRI within 3 months before primary liver transplantation. Dynamic imaging was performed before (unenhanced) and after (hepatic arterial, portal venous, equilibrium, and 1-hour delayed phases) IV bolus administration of gadobenate dimeglumine at 0.1 mmol/kg body weight. Retrospective image analysis to detect HCC nodules was performed independently by two abdominal radiologists who had no pathologic information. On a per-nodule basis, the sensitivity and positive predictive value were calculated for the two observers. Sensitivity and specificity in the diagnosis of HCC also were evaluated. Fisher's exact test was performed to determine whether there was a detection difference between HCC nodules 1 cm in diameter or larger and nodules smaller than 1 cm and to evaluate the differences in causes of false-positive MRI findings based on lesion size (or= 1 cm vs 1 cm). RESULTS: Twenty-seven patients had 41 HCCs. In HCC detection, gadobenate dimeglumine-enhanced MRI had a sensitivity of 85% (35 of 41 HCCs) and a positive predictive value of 66% (35 of 53 readings) for observer 1 and a sensitivity of 80% (33 of 41 HCCs) and a positive predictive value of 65% (34 of 52 readings) for observer 2. For both observers, sensitivity in the detection of HCCs 1 cm in diameter and larger (91-94%) was significantly different (p 0.05) from that in detection of HCCs smaller than 1 cm (29-43%). Nonneoplastic arterial hypervascular lesions more often caused false-positive diagnoses of lesions smaller than 1 cm in diameter (80-86%) on MR images than of those 1 cm in diameter and larger (0-25%). The difference was statistically significant (p 0.05) for both observers. In diagnosis, gadobenate dimeglumine-enhanced MRI had a sensitivity of 87% (20 of 23 patients) and a specificity of 79% (19 of 24 patients) for both observers. CONCLUSION: Dynamic gadobenate dimeglumine-enhanced MRI has a sensitivity of 80-85% and a positive predictive value of 65-66% in the detection of HCC. The technique, however, is of limited value for detecting and characterizing lesions smaller than 1 cm in diameter.
机译:目的:本研究的目的是回顾性评估动态加多巴特二甲双胍增强磁共振成像与外植体病理学相关性在肝移植患者肝细胞癌(HCC)检测中的诊断性能。材料与方法:47例患者(男28例,女19例;平均年龄49岁)在原发性肝移植前3个月内接受了动态加多贝酸加二甲双胍增强MRI检查。动态成像在0.1毫摩尔/千克体重的静注加多贝酸二聚丁二胺静脉推注之前(未增强)和之后(肝动脉,门静脉,平衡和1小时延迟期)进行。由两名没有病理学信息的腹部放射科医师独立进行回顾性图像分析以检测HCC结节。在每个结节的基础上,计算了两位观察者的敏感性和阳性预测值。还评估了肝癌诊断的敏感性和特异性。进行Fisher精确测试以确定直径1厘米或更大的HCC结节与小于1厘米的结节之间是否存在检测差异,并根据病变大小(>或= 1)评估MRI假阳性结果的差异厘米vs <1厘米)。结果:27例患者有41例肝癌。在HCC检测中,加达贝特二甲双胍增强MRI对观察者1的敏感性为85%(41个HCC中的35个),阳性预测值为66%(53个读数中的35个),灵敏度为80%(41个HCC中的33个)观察者2的阳性预测值为65%(52个读数中的34个)。对于这两个观察者,直径1厘米及更大(91-94%)的HCC的检测灵敏度与该值显着不同(p <0.05)。检测小于1厘米(29-43%)的HCC。非肿瘤性动脉多血管病变在MR图像上比直径在1 cm或更大(0-25%)的病变更容易引起假阳性诊断,这些病变的直径小于1 cm(80-86%)。两位观察者的差异具有统计学意义(p <0.05)。在诊断中,加多贝酸加二甲双胍增强的MRI对两位观察者的敏感性为87%(23名患者中的20名),特异性为79%(24名患者中的19名)。结论:动态加多巴酸盐二甲双胍增强MRI对HCC的检测灵敏度为80-85%,阳性预测值为65-66%。但是,该技术对于检测和表征直径小于1厘米的病变具有有限的价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号